Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.71 USD
Change Today -0.02 / -1.16%
Volume 9.1K
PIP On Other Exchanges
As of 8:04 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

pharmathene inc (PIP) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/10/14 - $2.59
52 Week Low
08/6/14 - $1.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PHARMATHENE INC (PIP)

pharmathene inc (PIP) Related Businessweek News

No Related Businessweek News Found

pharmathene inc (PIP) Details

PharmAthene, Inc., a biodefense company, develops and commercializes medical counter measures against biological and chemical threats in the United States. Its product candidates include SparVax, a recombinant protective antigen anthrax vaccine for post-exposure prophylaxis in conjunction with antibiotics and general use prophylaxis; Valortim, a human monoclonal antibody to protect against and treat human inhalational anthrax; and recombinant butyrylcholinesterase bioscavenger, a medical countermeasure for nerve agent poisoning by organophosphorous compounds comprising nerve gases and pesticides. The company serves the Biomedical Advanced Research and Development Authority, Chemical Biological Medical Systems, and the National Institute of Allergy and Infectious Diseases. It has collaboration with Bristol-Myers Squibb for developing Valortim; and strategic alliance with Nanotherapeutics, Inc. to develop biodefense programs. The company is headquartered in Annapolis, Maryland.

35 Employees
Last Reported Date: 03/11/15

pharmathene inc (PIP) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

pharmathene inc (PIP) Key Developments

PharmAthene to Develop New Anthrax Vaccine with Immunovaccine

PharmAthene has entered into an exclusive agreement with vaccine and immunotherapy company Immunovaccine to co-develop an commercialize an Anthrax vaccine formulated using Immunovaccine's proprietary DepoVax vaccine platform.

PharmAthene, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

PharmAthene, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported contract revenue of $7,068,746 against $3,742,525 a year ago. Income from operations was $1,161,084 against loss from operations was $2,401,866 a year ago. Net income before provision for income taxes was $1,483,200 against net loss before provision for income taxes was $2,228,735 a year ago. Net income was $1,463,395 or $0.02 basic and diluted per share against net loss was $2,258,440 or $0.04 basic and diluted per share a year ago. The increase was primarily due to revenue recognition of a one-time payment of $5.8 million related to the audit by BARDA of indirect costs or rates charged by PharmAthene on the SparVax® contract for the years 2008 through 2013. The $5.8 million represented the difference between actual rates (i.e., actual cost to PharmAthene) and the provisional rates used to calculate previously billed and recognized revenue.

PharmAthene, Inc., Annual General Meeting, Jun 10, 2015

PharmAthene, Inc., Annual General Meeting, Jun 10, 2015., at 10:00 US Eastern Standard Time. Location: offices of Dentons US LLP at 1301 K Street. Agenda: To elect up to six (6) directors to the Board of Directors to serve until 2016 Annual Meeting of Stockholders and until their successors have been elected and qualified; to consider and provide an advisory (non-binding) vote to approve the compensation of named executive officers as described in the proxy statement; to ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as independent registered accounting firm for the fiscal year ending December 31, 2015; and to transact such other business as may properly come before the Annual Meeting and any adjournment or postponement of the Annual Meeting.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PIP:US $1.71 USD -0.02

PIP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bavarian Nordic A/S kr317.50 DKK -12.50
Baxter International Inc $38.50 USD +0.41
Bioporto A/S kr2.54 DKK +0.03
Chimerix Inc $52.69 USD -1.02
Emergent BioSolutions Inc $32.40 USD -1.20
View Industry Companies

Industry Analysis


Industry Average

Valuation PIP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.1x
Price/Book 5.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMATHENE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at